Nabriva Therapeutics plc logo
Nabriva Therapeutics plc NBRV

Quarterly report 2023-Q1
added 05-22-2023

report update icon

Nabriva Therapeutics plc Financial Statements 2011-2026 | NBRV

Annual Financial Statements Nabriva Therapeutics plc

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

4.1 M 787 K 1.23 M 1.04 B 970 M 1.98 B 176 M 179 M - - - -

Shares

2.68 M 1.73 M 514 K 74.2 M 50.8 M 29.8 M 2.15 M 2.12 M - - - -

Historical Prices

1.53 0.454 2.39 13.5 19.8 51.4 108 90.1 - - - -

Net Income

-57.2 M -49.4 M -69.5 M -82.8 M -115 M -74.4 M -54.9 M -31.4 M -16.3 M 15.5 M - -

Revenue

36.9 M 28.9 M 5.03 M 7.75 M 6.5 M - - - - - - -

Cost of Revenue

28.6 M 13.1 M 766 K 70 K - - - - - - - -

Gross Profit

- - - 7.68 M - - - - - - - -

Operating Income

-55.5 M -48.5 M -66.1 M -79.5 M -114 M -73.8 M -55 M -27.8 M -10.7 M - - -

Interest Expense

698 K 901 K 1.65 M 3.39 M 133 K 43 K 75 K 22.1 M 2.91 M - - -

EBITDA

-55.3 M -48.2 M -65.7 M -78.7 M -114 M -73.3 M -54.4 M -23.3 M -9.75 M 28.1 M - -

Operating Expenses

- - - 87.2 M 121 M 73.8 M - - - - - -

General and Administrative Expenses

45.3 M 51.6 M 55.3 M - 41.7 M 29.5 M 13.4 M 7.77 M 3.46 M 3.91 M - -

All numbers in USD currency

Quarterly Income Statement Nabriva Therapeutics plc

2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

3.2 M 3.2 M 2.73 M - 2.35 M 2.27 M 2.02 M 40.6 M 26.4 M 21.1 M 14.5 M 11.3 M 9.46 M 9.45 M 75.2 M 72.5 M 68.7 M 67 M 58.4 M 40.5 M 36.9 M 36.7 M 28.1 M 27.2 M 2.72 M 2.72 M 21.3 M 21.3 M 2.12 M - - - - - - - - - - - - - - - - - - - -

Net Income

-8.7 M - -11.5 M -11.1 M -11.8 M - -10.7 M -11.8 M -14 M - -13 M -15.4 M -23.3 M -23 M -17.8 M -21.7 M -20.2 M -30.8 M -52.8 M -17.8 M -13.3 M -22.3 M -22.3 M -14.6 M -15.2 M -15.2 M -14 M -12.1 M -13.6 M -7.96 M -8.42 M -24.5 M -6.06 M - - - - - - - - - - - - - - - -

Revenue

7.59 M - 9.15 M - 8.02 M - 8.86 M 8.24 M 2.53 M - 1.29 M 487 K 789 K 333 K 6.92 M 525 K 1.7 M 797 K 461 K 847 K 7.55 M 1.12 M 1.47 M 1.05 M 1.68 M - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

4.44 M - 4.42 M - 3.36 M - 4.2 M 3.62 M 62 K - 25 K 368 K 8 K - 15 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-8.48 M - -11.2 M - -11.6 M - -10.8 M -11.4 M -13.4 M - -13.2 M -14.5 M -20.2 M -22.1 M -17.2 M -21 M -19.2 M -30.9 M -52.9 M -17.7 M -12.9 M -22.3 M -20.7 M -15.6 M -15.2 M -14.7 M -14.1 M -11.5 M -14.7 M -10.2 M -8.33 M -5.52 M -3.67 M - - - - - - - - - - - - - - - -

Interest Expense

-31 K - 354 K - 308 K - 131 K 241 K 222 K - 256 K 251 K 1.02 M - 709 K 904 K 899 K - 8 K 7 K 4 K - 42 K 3 K 1 K - 35 K - 18 K - - - - - - - - - - - - - - - - - - - -

EBITDA

-8.45 M - -11 M - -11.5 M - -10.5 M -11.4 M -13.3 M - -12.9 M -14.2 M -20.1 M -22.1 M -17 M -20.7 M -19.1 M -30.9 M -52.5 M -17.4 M -12.7 M -22.3 M -20.4 M -15.4 M -15.1 M -14.7 M -13.9 M -11.4 M -14.7 M -10.2 M -8.33 M -5.52 M -3.67 M - - - - - - - - - - - - - - - -

Operating Expenses

- - - - - - - - - - - - - - - 21.5 M 20.9 M 31.7 M 53.4 M 18.6 M 20.4 M 23.4 M 22.2 M 16.6 M 16.9 M 17 M 15 M 13.3 M 16.1 M 11.2 M 9.62 M 6.42 M 4.27 M - - - - - - - - - - - - - - - -

General and Administrative Expenses

9 M - 11.9 M - 12.7 M - 12.3 M 12.9 M 12 M - 11 M 10.7 M 16 M - 18.5 M 13.4 M 13.4 M - 12.6 M 8.84 M 10.1 M - 9.52 M 5.57 M 4.22 M - 2.99 M 3.37 M 3.08 M - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Nabriva Therapeutics plc NBRV
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Nabriva Therapeutics plc plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Ultragenyx Pharmaceutical Ultragenyx Pharmaceutical
RARE
$ 19.23 -3.85 % $ 1.9 B usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
RedHill Biopharma Ltd. RedHill Biopharma Ltd.
RDHL
$ 0.8 0.89 % $ 428 M israelIsrael
Dr. Reddy's Laboratories Limited Dr. Reddy's Laboratories Limited
RDY
$ 13.56 -1.56 % $ 2.25 B indiaIndia
Regeneron Pharmaceuticals Regeneron Pharmaceuticals
REGN
$ 742.02 -1.94 % $ 77.6 B usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Replimune Group Replimune Group
REPL
$ 7.22 -4.24 % $ 582 M usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
REGENXBIO REGENXBIO
RGNX
$ 7.88 -4.6 % $ 406 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Rigel Pharmaceuticals Rigel Pharmaceuticals
RIGL
$ 26.2 -0.64 % $ 471 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
Avidity Biosciences Avidity Biosciences
RNA
$ 13.09 -0.08 % $ 1.8 B usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Avid Bioservices Avid Bioservices
CDMO
- - $ 789 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Rhythm Pharmaceuticals Rhythm Pharmaceuticals
RYTM
$ 78.52 -4.13 % $ 5.1 B usaUSA
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
$ 12.57 -9.96 % $ 1.91 B usaUSA
Sana Biotechnology Sana Biotechnology
SANA
$ 2.78 -8.42 % $ 704 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
SIGA Technologies SIGA Technologies
SIGA
$ 5.35 7.76 % $ 383 M usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
$ 321.71 -1.96 % $ 42.1 B usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Cara Therapeutics Cara Therapeutics
CARA
- -3.03 % $ 260 M usaUSA
ChemoCentryx ChemoCentryx
CCXI
- - $ 3.74 B usaUSA
Silence Therapeutics plc Silence Therapeutics plc
SLN
$ 4.8 -9.6 % $ 622 M britainBritain
Enlivex Therapeutics Ltd. Enlivex Therapeutics Ltd.
ENLV
$ 1.08 -0.92 % $ 22.2 M israelIsrael
Enochian Biosciences Enochian Biosciences
ENOB
- - $ 40.5 M usaUSA